CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Biosimilars

BIOSIMILARS: BIOCON BIOLOGICS

null

Healthcare today

Reducing the health inequality

Over 2 billion people worldwide cannot afford life-saving medicines, which puts their lives at risk. Making potentially life-saving drugs more affordable and accessible can help patients live a prolonged and better quality of life as well as reduce the health inequality. Controlling drug expenditure could also be key to preventing future health care cost inflation, given the multiple challenges that burden the healthcare system worldwide due to an ageing and growing population, burgeoning middle class, complexities of cancer, diabetes, and other non-communicable diseases.

Biological medications are at the forefront of medical advances today but their formidable cost consumes a significant portion of public and private drug spending. In comparison, biosimilars (a highly similar version of biologics), offer an equally effective option at an affordable cost, which offers the promise of a more sustainable solution. Healthcare must take many forms and should be made accessible to people of all socio-economic backgrounds.

Making potentially life-saving drugs more affordable and accessible can help patients live a prolonged and better quality of life as well as reduce the health inequality.

Healthcare should be made accessible to people of all socio-economic backgrounds.

null

Understanding
Biologics

Transforming treatments for life-threatening illnesses

Biologic medicines contain substances that are made by living cells or organisms. They are usually made of proteins that are naturally produced in the human body.

More >> 

null

Understanding
Biosimilars

Achieving a sustainable health equity

Biosimilars are safe, effective and highly similar versions of approved and authorised biological medicines. They treat the same diseases as the reference biological medicine and with the same efficacy.

More >> 

Biocon Biologics

Biocon is giving patients a new lifeline

Biocon Biologics is a subsidiary of Biocon with a focus on Biocon’s Biosimilars business. It is advancing a range of high-quality, safe and effective biosimilars that offer affordable solutions to expensive biologic medicines. Biosimilars offer the same quality as the originator biologics but are relatively inexpensive, which makes it more affordable for patients. Having recognised the role of biosimilars in addressing issues of access and affordability, Governments and regulatory agencies have introduced several measures to support biosimilar development and approval, encourage uptake across multiple indications, and foster reimbursement.

Biocon Biologics’ exceptional scientific talent pool and world class R&D infrastructure for developing and manufacturing complex biosimilars together with the commercialisation strengths of our partners, position us well to be a global leader in the biosimilars space over the long term. By offering greater patient access to affordable treatment we are providing a viable path to cost reduction and sustainable health equity.

More >>

null

Biosimilars facilitate greater patient access to affordable treatment and provide a viable path to cost reduction and quality improvement and offer a sustainable health equity.

Biocon Shares Vision 2022 | Christiane Hamacher of Biocon Biologics To ET NOW

Dr. Christiane Hamacher, Managing Director & CEO, Biocon Biologics India Limited

CORPORATE GOVERNANCE
KEY THERAPEUTIC AREAS
RESEARCH SERVICES
OUR CULTURE
RESPONSIBILITY
Share